(Reuters) - Johnson & Johnson (NYSE: JNJ) sued Samsung (KS: 005930) Bioepis for allegedly breaching a contract agreement over ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Lowering the price of the 2.5 mg dose vial to $349 per month. Lowering the price of the 5 mg dose vial to $499 per month.

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Over the last 7 days, the United States market has dropped 3.0%, yet it remains up by 18% over the past year with earnings forecasted to grow by 14% annually. In such a dynamic environment, ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Over the last 7 days, the United States market has experienced a 3.0% decline, though it remains up by 18% over the past year with earnings forecasted to grow annually by 14%. In this context of ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

On February 13, the House Budget Committee, voting 21-16 along party lines (Republicans in favor and Democrats opposed), passed a 2025 ...

Private fund managers “recycle” capital — i.e., reinvest capital that would otherwise be returned to investors or to recall distributions already ...